Utah Biotech Startup Claims Breakthrough in Lab-Grown Human Sperm Technology
核心洞察
Paterna Biosciences (搜索) reports successful creation of functional human sperm from testicular stem cells using computational biology and proprietary growth factors, potentially revolutionizing male infertility treatment.
The company has used lab-grown sperm to create test embryos, though the work has not yet been peer-reviewed or independently verified by external laboratories.
The technology could offer new hope for men with complete absence of sperm in ejaculate, who currently have limited treatment options for biological parenthood.
Salt Lake City-based biotech company Paterna Biosciences (搜索) has announced what it claims is the world's first successful in vitro human spermatogenesis, growing functional human sperm in laboratory conditions and using them to create test embryos. The breakthrough, if verified, could transform fertility treatment for men with severe infertility conditions.
Revolutionary Approach to Sperm Production
The company's process involves isolating sperm-making stem cells from testicular tissue and coaxing them into becoming fully developed sperm in laboratory dishes. According to Alexander Pastuszak, CEO and cofounder of Paterna and an associate professor of surgery at the University of Utah School of Medicine (搜索), "We've figured out the instructions that are needed to teach these stem cells to become mature, normal sperm."
The team utilized computational biology to predict molecular signals crucial at every stage of the sperm-making process, then tested various combinations of molecules to induce each developmental stage. This approach differs from previous attempts that focused on culturing entire testicular tubules, which Paterna found less effective.
Addressing Critical Medical Need
Roughly half of all infertility cases are linked to male factors, including low sperm count, abnormal sperm shape, or poorly swimming sperm. About 10 to 15 percent of infertile men have a complete absence of sperm in their ejaculate and currently have few options for having biological children. This population represents Paterna's initial target market.
"In terms of male infertility, the most challenging scenarios for clinicians are where men don't have any sperm," says Ryan Flannigan, a surgeon specializing in sperm retrieval at the Vancouver Prostate Centre (搜索) in Canada. "You see the emotional toll and the impact on these individuals and couples."
Technical Validation and Safety Measures
Pastuszak reports that early testing shows the lab-made sperm look "effectively identical" to naturally produced sperm. The company has demonstrated a high success rate in generating sperm from dozens of tissue samples and claims the goal is to create thousands of sperm from a standard tissue biopsy.
The embryos created using lab-grown sperm were developed solely as validation tests, not for pregnancy initiation. Paterna plans comprehensive studies comparing eggs fertilized with extracted sperm to those fertilized with lab-made sperm, followed by detailed screening of resulting embryos for physical and genetic abnormalities.
Clinical Pathway and Market Potential
The technology is designed to replace current surgical procedures that search for sperm in testicular tissue, which require general anesthesia and can take up to four hours. Paterna's approach would instead use a small testicular tissue biopsy performed in a doctor's office, with the tissue sent to the company for in vitro spermatogenesis processing.
The company plans to charge between $5,000 and $12,000 for the procedure and anticipates clinical trials could begin as soon as next year. Larry Lipshultz, a professor of urology at Baylor College of Medicine, called the development "huge," noting that "people didn't understand, or had never figured out, what growth factors you have to supply to these cells to get them to become mature sperm."
Scientific Scrutiny and Regulatory Challenges
The work has not yet been published in a peer-reviewed journal, and no independent laboratory has verified the results. This lack of external validation has drawn comparisons to previous claims in the field, including a 2015 announcement by French startup Kallistem that faced subsequent scientific scrutiny regarding whether full spermatogenesis had been achieved.
The technology is expected to face years of additional research and regulatory review before clinical availability. Bioethicists and reproductive medicine specialists emphasize the need for strong oversight, extensive genetic screening of embryos, and public debate about appropriate use of such technology.
Broader Applications and Future Implications
Beyond treating male infertility, the technology could potentially help young cancer patients who undergo chemotherapy before puberty. While these patients can currently freeze testicular tissue, transplanting it back remains experimental with no reported births to date.
Justin Dubin, a urologist at Baptist Health Miami Cancer Institute (搜索), noted that while the advance is exciting, cost will be a limiting factor. "We're coming up with so many amazing options in fertility care, and yet so many of them are not covered by insurance," he said. "It's a huge disservice to our patients, to the world's population, by not providing people with the means to achieve the family that they want."